This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bermudez, L. E.
Right arrow Articles by Young, L. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bermudez, L. E.
Right arrow Articles by Young, L. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1999, p. 1870-1874, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Mefloquine Is Active In Vitro and In Vivo against Mycobacterium avium Complex

Luiz E. Bermudez,1,* Peter Kolonoski,1 Martin Wu,1 Priscilla A. Aralar,2 Clark B. Inderlied,2 and Lowell S. Young1

Kuzell Institute for Arthritis and Infectious Diseases, San Francisco,1 and Department of Pathology and Laboratory Medicine, Children's Hospital of Los Angeles, University of Southern California, Los Angeles,2 California

Received 16 February 1999/Returned for modification 23 April 1999/Accepted 11 May 1999

Despite the development of several agents, new classes of antimicrobials with activity against the Mycobacterium avium complex (MAC) are needed. Based on a broad screening of compounds, we found that mefloquine has MICs of 8 to 16 µg/ml by the BACTEC system and 16 µg/ml by broth microdilution for five MAC strains tested. An expansion of the screening with broth microdilution to 24 macrolide-susceptible strains and 6 macrolide-resistant strains determined that the MIC for all strains was 16 µg/ml. To determine the intracellular activity of mefloquine, U937 macrophage monolayers infected with MAC strain 101, 100, or 109 (serovars 1, 8, and 4) were treated with mefloquine daily, and the number of intracellular bacteria was quantitated after 4 days. Significant growth inhibition against the three MAC strains at concentrations greater than or equal to 10 µg/ml (P < 0.05) was obtained. Due to the encouraging anti-MAC activity, in vivo efficacy in beige mice infected with MAC 101 was evaluated. Animals were treated with 5, 10, 20, or 40 mg/kg of body weight daily, three times a week, twice a week, or once a week for 4 weeks, and bacteria were quantitated in blood, liver, and spleen. No toxicity was observed with any of the treatment regimens. Mefloquine had borderline bactericidal activity at a dosage of 40 mg/kg daily (100% inhibition compared with a 1-week control), and significant inhibition was obtained at dosages of 40 mg/kg three times a week, as well as 20 mg/kg daily. Mefloquine had no significant effect on bacteremia. A combination of mefloquine and ethambutol showed significantly more activity than did either drug alone in liver, spleen, and blood; the combination was also bactericidal against M. avium. Although safety is a potential concern, mefloquine and related compounds deserve further investigation as anti-MAC therapies.

* Corresponding author. Mailing address: Kuzell Institute, 2200 Webster St., Suite 305, San Francisco, CA 94115. Phone: (415) 561-1734. Fax: (415) 441-8548. E-mail: luizb{at}cooper.cpmc.org.

Antimicrobial Agents and Chemotherapy, August 1999, p. 1870-1874, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Sousa, M., Pozniak, A., Boffito, M. (2008). Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother 62: 872-878 [Abstract] [Full Text]  
  • Bermudez, L. E., Motamedi, N., Chee, C., Baimukanova, G., Kolonoski, P., Inderlied, C., Aralar, P., Wang, G., Phan, L. T., Young, L. S. (2007). EDP-420, a Bicyclolide (Bridged Bicyclic Macrolide), Is Active against Mycobacterium avium. Antimicrob. Agents Chemother. 51: 1666-1670 [Abstract] [Full Text]  
  • Shimizu, T., Tomioka, H. (2006). Activity of Picolinic Acid in Combination with the Antiprotozoal Drug Quinacrine against Mycobacterium avium Complex.. Antimicrob. Agents Chemother. 50: 3186-3188 [Abstract] [Full Text]  
  • Danelishvili, L., Wu, M., Young, L. S., Bermudez, L. E. (2005). Genomic Approach to Identifying the Putative Target of and Mechanisms of Resistance to Mefloquine in Mycobacteria. Antimicrob. Agents Chemother. 49: 3707-3714 [Abstract] [Full Text]  
  • Bermudez, L. E., Kolonoski, P., Seitz, L. E., Petrofsky, M., Reynolds, R., Wu, M., Young, L. S. (2004). SRI-286, a Thiosemicarbazole, in Combination with Mefloquine and Moxifloxacin for Treatment of Murine Mycobacterium avium Complex Disease. Antimicrob. Agents Chemother. 48: 3556-3558 [Abstract] [Full Text]  
  • Cangelosi, G. A., Freeman, R. J., Lewis, K. N., Livingston-Rosanoff, D., Shah, K. S., Milan, S. J., Goldberg, S. V. (2004). Evaluation of a High-Throughput Repetitive-Sequence-Based PCR System for DNA Fingerprinting of Mycobacterium tuberculosis and Mycobacterium avium Complex Strains. J. Clin. Microbiol. 42: 2685-2693 [Abstract] [Full Text]  
  • Cangelosi, G. A., Palermo, C. O., Bermudez, L. E. (2001). Phenotypic consequences of red-white colony type variation in Mycobacterium avium. Microbiology 147: 527-533 [Abstract] [Full Text]  
  • Bermudez, L. E., Inderlied, C. B., Kolonoski, P., Petrofsky, M., Aralar, P., Wu, M., Young, L. S. (2001). Activity of Moxifloxacin by Itself and in Combination with Ethambutol, Rifabutin, and Azithromycin In Vitro and In Vivo against Mycobacterium avium. Antimicrob. Agents Chemother. 45: 217-222 [Abstract] [Full Text]  
  • Kunin, C. M., Ellis, W. Y. (2000). Antimicrobial Activities of Mefloquine and a Series of Related Compounds. Antimicrob. Agents Chemother. 44: 848-852 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»